We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pulmatrix announced the US Food and Drug Administration (FDA) completed its review of our Investigational New Drug (IND) Application and notified the Company that we are authorized to initiate a Phase 2 clinical investigation for ...